Argo Biopharma Welcomes Dr. Gena Wang as CFO and Chief Strategy Officer

Argo Biopharmaceutical Co., Ltd., a pioneering entity in the clinical-stage biotechnology realm, has announced a significant addition to its executive team with the appointment of Dr. Gena Wang as the Chief Financial Officer and Chief Strategy Officer, effective March 1, 2026. Dr. Wang, who comes to Argo Biopharma with nearly 20 years of rich experience in biopharmaceutical capital markets and strategic advisory roles, is expected to leverage her expertise to enhance the company's growth trajectory.

Dr. Wang previously held a central role at Barclays as Managing Director and senior equity research analyst focusing on the biotechnology sector. Throughout her illustrious career, she has become a trusted figure in the investment community, known for her thorough research into novel therapies, particularly those centered around RNA, gene, and cell technologies, as well as her insights into rare diseases and oncology treatments.

Dr. Dongxu Shu, co-founder and CEO of Argo Biopharma, expressed enthusiasm over Dr. Wang’s appointment, stating, “Her deep knowledge of genetic medicines and her established connections within both the financial and healthcare sectors make her irreplaceable as we advance our product pipeline and grow.” This enthusiasm is echoed by Dr. Wang herself, who commented, “I am excited to join Argo Biopharma at such a pivotal time. The company’s innovative siRNA platform stands as a beacon of hope in potentially delivering groundbreaking treatments across a wide spectrum of diseases.”

Dr. Wang’s transition to Argo Biopharma is marked by a distinguished history of leading therapeutic teams during her tenure at Barclays. Furthermore, she has contributed significantly to several leading investment firms, including Jefferies and Leerink Partners, where her analyses frequently centered on biotechnology companies pioneering in RNA therapies and other advanced treatment modalities.

Recognized consistently among the top analysts in Institutional Investor's All-America Equity Research Team since 2018, Dr. Wang also possesses a Ph.D. in Molecular and Cell Biology from the State University of New York and has conducted postdoctoral research at the prestigious Rockefeller University, specializing in RNA. In addition to her academic credentials, she holds the prestigious Chartered Financial Analyst (CFA) designation, further underscoring her robust grounding in both science and finance.

Argo Biopharma, which is dedicated to developing next-generation RNA interference (RNAi) therapeutics, is ushering in a new chapter of innovation in the biopharmaceutical industry. With a diverse pipeline that includes RNAi candidate treatments for various conditions such as cardiovascular issues, viral infections, metabolic disorders, and rare diseases, the company is poised for significant advancements in patient care.

The decision to bring Dr. Gena Wang on board reflects the company’s commitment to strengthening its leadership and resource framework to facilitate growth and innovation. As Argo Biopharma enters its next phase, the integration of Dr. Wang’s vast experience is expected to play a crucial role in navigating the complexities of financial strategy and operational efficiency in the biotech market.

As the company moves forward, stakeholders and patients alike can look forward to the potential of transformative therapeutics that promise to reshape the treatment landscape. For more information about Argo Biopharma and its innovative pipeline, visit www.argobiopharma.com.